The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Cynthia M. Simbulan-Rosenthal 1,* , Sivanesan Dakshanamurthy 1,2,* , Anirudh Gaur 1 , You-Shin Chen 1 , Hong-Bin Fang 3 , Maryam Abdussamad 4 , Hengbo Zhou 4 , John Zapas 4 , Valerie Calvert 5 , Emanuel F. Petricoin 5 , Michael B. Atkins 2 , Stephen W. Byers 1,2 and Dean S. Rosenthal 1 1 Department of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, DC, USA 2 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA 3 Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA 4 MedStar Franklin Square Medical Center, Baltimore, MD, USA 5 Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA * These authors are co-first authors Correspondence to: Dean S. Rosenthal, email: // Keywords : mebendazole, drug repurposing, melanoma, ERK pathway, BRAF Received : March 31, 2016 Accepted : October 13, 2016 Published : February 02, 2017 Abstract Structure-based drug repositioning in addition to random chemical screening is now a viable route to rapid drug development. Proteochemometric computational methods coupled with kinase assays showed that mebendazole (MBZ) binds and inhibits kinases important in cancer, especially both BRAF WT and BRAF V600E . We find that MBZ synergizes with the MEK inhibitor trametinib to inhibit growth of BRAF WT -NRAS Q61K melanoma cells in culture and in xenografts, and markedly decreased MEK and ERK phosphorylation. Reverse Phase Protein Array (RPPA) and immunoblot analyses show that both trametinib and MBZ inhibit the MAPK pathway, and cluster analysis revealed a protein cluster showing strong MBZ+trametinib - inhibited phosphorylation of MEK and ERK within 10 minutes, and its direct and indirect downstream targets related to stress response and translation, including ElK1 and RSKs within 30 minutes. Downstream ERK targets for cell cycle, including cMYC, were down-regulated, consistent with S- phase suppression by MBZ+trametinib, while apoptosis markers, including cleaved caspase-3, cleaved PARP and a sub-G1 population, were all increased with time. These data suggest that MBZ, a well-tolerated off-patent approved drug, should be considered as a therapeutic option in combination with trametinib, for patients with NRAS Q61mut or other non-V600E BRAF mutant melanomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“The latest technologies used for new drug discovery are in part intended to circumvent these challenges, and while the number of new molecular entities introduced in 2014 increased, trends in drug development have been variable [3].”
Simplified calculation of body surface area
(1987) · New England Journal of Medicine · doi:10.1056/nejm198710223171717 · Cited by 3,238
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
Doudican, N., Rodriguez, A., Osman, I., & Orlow, S. J. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2159 · Cited by 152 · cited 3×
“MBZ inhibits growth of melanoma cell lines in vitro and in vivo, accompanied by changes in tubulin polymerization, BCL2 phosphorylation and apoptosis [14].”
BackgroundResultRepositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
Nygren, P., Fryknäs, M., Ågerup, B., & Larsson, R. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1539-5 · Cited by 133
Nygren, P., & Larsson, R. (2014) · Acta Oncologica · doi:10.3109/0284186x.2013.844359 · Cited by 83
Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma
Dobrosotskaya, I. Y., Hammer, G. D., Schteingart, D. E., Maturen, K. E., & Worden, F. P. (2011) · Endocrine Practice · doi:10.4158/ep10390.cr · Cited by 53 · cited 1×
“In the former case, some regression in metastatic lesions were observed, and the cancer remained stable on MBZ monotherapy, with the patient tolerating treatment without side effects until progression at 24 months [15].”
Background
Cited by
Guerini, A. E., Triggiani, L., Maddalo, M., Bonù, M. L., Frassine, F., Baiguini, A., Alghisi, A., Tomasini, D., Borghetti, P., Pasinetti, N., et al. (2019) · Cancers · doi:10.3390/cancers11091284 · Cited by 146
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022) · Cancers · doi:10.3390/cancers14194601 · Cited by 55
Drug repurposing: An emerging strategy in alleviating skin cancer
Kumbhar, P., Kole, K., Yadav, T., Bhavar, A., Waghmare, P., Bhokare, R., Manjappa, A., Jha, N. K., Chellappan, D. K., Shinde, S., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175031 · Cited by 28
Metadata
- Authors
- Simbulan-Rosenthal, C. M., Dakshanamurthy, S., Gaur, A., Chen, Y.-S., Fang, H.-B., Abdussamad, M., Zhou, H., Zapas, J., Calvert, V., Petricoin, E. F., Atkins, M. B., Byers, S. W., & Rosenthal, D. S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-02-02
- Volume
- 8
- Issue
- 8
- Pages
- 12576-12595
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2584349229
- Cited by
- 63
- References
- 7
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. https://app.cochat.ai/papers/10.18632/oncotarget.14990
- The paper
- Simbulan-Rosenthal, C. M., Dakshanamurthy, S., Gaur, A., Chen, Y.-S., Fang, H.-B., Abdussamad, M., Zhou, H., Zapas, J., Calvert, V., Petricoin, E. F., Atkins, M. B., Byers, S. W., & Rosenthal, D. S. (2017). The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Oncotarget. https://doi.org/10.18632/oncotarget.14990
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.